147 related articles for article (PubMed ID: 17998090)
1. Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
Hu M; Scollard D; Chan C; Chen P; Vallis K; Reilly RM
Nucl Med Biol; 2007 Nov; 34(8):887-96. PubMed ID: 17998090
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
Bailey KE; Costantini DL; Cai Z; Scollard DA; Chen Z; Reilly RM; Vallis KA
J Nucl Med; 2007 Sep; 48(9):1562-70. PubMed ID: 17704253
[TBL] [Abstract][Full Text] [Related]
4. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy.
Fonge H; Lee H; Reilly RM; Allen C
Mol Pharm; 2010 Feb; 7(1):177-86. PubMed ID: 19924993
[TBL] [Abstract][Full Text] [Related]
6. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
Cai Z; Chen Z; Bailey KE; Scollard DA; Reilly RM; Vallis KA
J Nucl Med; 2008 Aug; 49(8):1353-61. PubMed ID: 18632822
[TBL] [Abstract][Full Text] [Related]
7. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
[TBL] [Abstract][Full Text] [Related]
8. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
Cornelissen B; Darbar S; Hernandez R; Kersemans V; Tullis I; Barber PR; Smart S; Vojnovic B; Reilly R; Vallis KA
J Nucl Med; 2011 May; 52(5):776-83. PubMed ID: 21498540
[TBL] [Abstract][Full Text] [Related]
9. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
Reilly RM; Kiarash R; Cameron RG; Porlier N; Sandhu J; Hill RP; Vallis K; Hendler A; Gariépy J
J Nucl Med; 2000 Mar; 41(3):429-38. PubMed ID: 10716315
[TBL] [Abstract][Full Text] [Related]
10. Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice.
Tolmachev V; Orlova A; Wei Q; Bruskin A; Carlsson J; Gedda L
Cancer Biother Radiopharm; 2004 Aug; 19(4):491-501. PubMed ID: 15453964
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
Reilly RM; Chen P; Wang J; Scollard D; Cameron R; Vallis KA
J Nucl Med; 2006 Jun; 47(6):1023-31. PubMed ID: 16741313
[TBL] [Abstract][Full Text] [Related]
12. Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy.
Terry SY; Vallis KA
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1298-305. PubMed ID: 22336201
[TBL] [Abstract][Full Text] [Related]
13. Amplified delivery of indium-111 to EGFR-positive human breast cancer cells.
Wang J; Chen P; Su ZF; Vallis K; Sandhu J; Cameron R; Hendler A; Reilly RM
Nucl Med Biol; 2001 Nov; 28(8):895-902. PubMed ID: 11711308
[TBL] [Abstract][Full Text] [Related]
14. Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles.
Fonge H; Huang H; Scollard D; Reilly RM; Allen C
J Control Release; 2012 Feb; 157(3):366-74. PubMed ID: 21982897
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
16. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
[TBL] [Abstract][Full Text] [Related]
17. Comparative antiproliferative effects of (111)In-DTPA-hEGF, chemotherapeutic agents and gamma-radiation on EGFR-positive breast cancer cells.
Chen P; Mrkobrada M; Vallis KA; Cameron R; Sandhu J; Hendler A; Reilly RM
Nucl Med Biol; 2002 Aug; 29(6):693-9. PubMed ID: 12234595
[TBL] [Abstract][Full Text] [Related]
18. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
19. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]